Allergan may have a reputation as a serial buyer, but it’s not looking for any big deals, CEO Brent Saunders insisted on Monday. And that assurance could quiet the rumors that the company is eyeing a Biogen buy.
As Saunders pointed out on Allergan’s Q2 conference call, the company has been focused on so-called “stepping stone” deals, and that’s what it’s looking at now.
Allergan’s recently canceled Pfizer megamerger notwithstanding, “It’s not like it’s a new strategy, despite our image … in the market,” he said.
That was a “once in a corporate lifetime situation,” Saunders insisted. These days, “we’re not looking for big M&A,” he said, though “while the odds of something compelling become clear are exceptionally low,” they’re “not zero,” he pointed out.
Meanwhile, in the wake of Allergan’s just-closed deal to send its generics unit off to Teva–and another recent pact that’ll transfer its generics distribution business to the Israeli drugmaker, too–Teva’s base business “looks good,” Evercore ISI analyst Umer Raffat wrote in a note to clients. Key products Botox and Restasis netted $719.7 million and $390.6 million in quarterly sales, respectively, with their year-over-year growth offsetting a $38.2 million decline for now-off-patent Alzheimer’s med Namenda.
Overall, the heavy hitters led revenue to $3.68 billion–and while that figure fell short of the $4.08 billion consensus mark, that consensus hadn’t been updated for the generics distribution sale, Raffat pointed out. Allergan put up a net loss of $1.44 per share, which has widened since the company posted a loss of 80 cents in the year-ago period.
Allergan’s full-year guidance suffered on the distribution deal, too; while the business primarily supported the company’s former generics unit, branded revenues took a $100 million hit, leading the Dublin drugmaker to revise its sales guidance downward. It now expects between $14.75 billion and $15 billion for the year, as opposed to the $15 billion it previously forecast.
By Carly Helfan
Source: Fierce Pharma
Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.
Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.
On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.